Privately held Endospan, headquartered in Herzlia (Tel Aviv), Israel, is a pioneer in the endovascular repair of aortic arch disease including aneurysms and dissections. Endospan’s NEXUS™ Aortic Arch Stent Graft System is the first endovascular off-the-shelf system with CE Mark to treat a greatly underserved group of patients diagnosed with a dilative lesion in, or near the aortic arch. While minimally invasive endovascular repair has been the standard of care for Abdominal Aortic Aneurysm (AAA), Aortic Arch Disease patients with aneurysms or dissections have not been as fortunate and have had little choice but to undergo open-chest surgery with its invasiveness and risks, lengthy hospitalization periods, and prolonged recuperation. For additional information about Endospan, visit their website at www.endospan.com.
Location: Israel
Employees: 51-200
Total raised: $25M
Founded date: 2009
Investors 2
| Date | Name | Website |
| - | SCP Vitali... | scpvitalif... |
| - | Arkin Hold... | arkinholdi... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.07.2024 | - | $25M | - |
Mentions in press and media 2
| Date | Title | Description |
| 02.07.2024 | ENDOSPAN RECEIVES ADDITIONAL $25M FROM ARTIVION FOR NEXUS FDA APPROVAL PATH | HERZELIA, Israel, July 2, 2024 /PRNewswire/ -- Endospan Ltd ("Endospan"), an Israeli-based, privately-held developer of the NEXUS® Stent Graft System ("NEXUS"), announced today an agreement with Artivion, Inc ("Arti... |
| - | EndoSpan | “The NEXUS Aortic Arch Stent Graft System is designed to overcome the specific challenges of the aortic arch anatomy. Get information here.” |